At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
Thymoglobulin +1 moredrug
Likely dose
Thymoglobulin 1.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Single Center, Pilot Study of Pretransplant Thymoglobulin Administration and Early Corticosteroid Withdrawal in Living Donor Renal Transplant Recipients Under Mycophenolate Mofetil (MMF) and Tacrolimus Immunosuppression
In Brief
A Phase 4 clinical trial evaluating Thymoglobulin for Renal Transplant Rejection and Transplants and Implants. Completed, enrolled 11 participants across 1 site.
Detailed Summary
To determine how safe and effective giving Thymoglobulin before transplantation to patients who are going to be receiving kidney transplants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGenzyme, a Sanofi Company
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionJun 2010
Study CompletionJul 2010
TodayJul 2026
First PostedOct 13, 2008
Enrollment StartSep 1, 2008
Primary CompletionJun 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.7 years ago
Interventions
Thymoglobulindrug
Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
Thymoglobulindrug
Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF